Research programme: phosphodiesterase IV inhibitors - Celltech/Merck

Drug Profile

Research programme: phosphodiesterase IV inhibitors - Celltech/Merck

Alternative Names: PDE4 inhibitors research programme - Celltech/Merck

Latest Information Update: 21 Sep 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celltech Group
  • Developer Celltech Group; Merck & Co
  • Class
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 29 Sep 2003 Merck & Co. has extended the development period of its phosphodiesterase-IV inhibitors collaboration with Celltech Group
  • 25 Apr 2003 Preclinical trials in Asthma (PO)
  • 25 Apr 2003 Preclinical trials in Chronic obstructive pulmonary disease (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top